View profile

FarmaKology Newsletter - Issue #43



May 5 · Issue #43 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+4500 Subscribers ) !

Today's Startup
Kumuda’s approach has the potential to save human lives for as soon as tomorrow, but will take too long to implement via academia and conventional routes. Which is why Kumuda was created. We are able to put the power of this approach into the hands of any company doing drug discovery research and development via a scalable computational platform. The algorithm developed during our founder’s PhD effectively harnesses the wealth of large scale orthogonal data sets available to more effectively assess a target’s potential to be drugged. This dramatically improves our power to get to solutions faster. Hence, saving more lives. 
Praxis Precision Medicines, a clinical-stage, genetic neuroscience company, launched today with more than $100 million in financing since its inception from premier life science investors led by founding investor Blackstone Life Sciences (via prior Clarus funds in 2016) as well as Novo Holdings, Vida Ventures and other prominent funds. Praxis is deploying a precision medicine approach to develop high-impact therapies that target the underlying causal mechanisms of both prevalent and rare brain disorders with overlapping disease biology.
Gilead Sciences has committed to producing “millions more” treatment courses of its COVID-19 treatment remdesivir in 2021 “if required,” after the FDA granted the drug emergency use authorization Friday, enabling broader use of the antiviral drug in hospitalized patients with severe symptoms of the disease.“We intend to get that to patients in the early past of this next week,” Gilead chairman and CEO Daniel O’Day said  yesterday on CBS’ “Face the Nation.”
Ipsen, a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, today announced they entered into an option agreement by which Ipsen would acquire an exclusive license for the worldwide rights to a high-value oncology program.
Applied DNA Sciences Inc. today announced with its COVID-19 vaccine development partner Takis Biotech that the first injections of the DNA vaccine candidates against the Spike protein (product of the S gene) of the SARS-CoV-2 virus, cause of the COVID-19 disease, have produced neutralizing antibodies in test animals.
Research & Study
Episode 109: Scott Gottlieb on Covid-19 treatments, reopening America, and going on TV every day by STAT | Free Listening on SoundCloud
Job Opportunities
Upcoming Webinar
Big Pharma and coronavirus vaccine development | COVID-19 Special
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue